Clinical Trial Update: D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia [Phase 4]

View source ↗

Summary

Phase 4 trial update comparing D-dimer adjusted vs therapeutic-dose low-molecular-weight heparin in hospitalized COVID-19 pneumonia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Ain Shams University | Conditions: Coronavirus Disease (COVID)19 | Phase 4 | Status: UNKNOWN